AivoCode is a neuroscience-focused biotech pioneering development of broad platform technologies to improve treatment and management of neurological diseases such as brain injury, Alzheimers disease and other neurodegenerative disorders. Anchored in technology licensed from Sanford Burnham Prebys Medical Discovery Institute (SBP), Aivocode is addressing improved delivery of therapeutic or an imaging payload from systemic circulation to the injured part of brain. It is estimated that in the US alone, some 2.5M persons annually experience a form of Traumatic brain injury (TBI). Given the limited treatment options currently for these conditions, Aivocode's technology has the potential to change the clinical management of TBI. is The most common progressive neurodegenerative disorder - generally associated with aging - is Alzheimers disease (AD) with available treatments probably being offered too late the disease development process. AivoCode is developing specific probes that recognize AD signature present in the brain. These probes can be used for therapeutic delivery and non-invasive detection of early AD. A third area of interest is Multiple Sclerosis (MS) - an immune-mediated inflammatory disease affecting brain, nerve and spinal cord tissue affecting more than 2 million people. The disease causes demyelination of neurons, axonal damage, and neurodegeneration. AivoCodes platform technology is selective to CNS lesions characteristic of MS.
